Ropivacaine

CAS No:
84057-95-4 Category:
  • #LGM Pharma is a Ropivacaine CAS# 84057-95-4 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 84057-95-4
  • AHFC code: 12:00.0
  • Synonyms: Ropivacaina [INN-Spanish] Ropivacaina [Spanish] Ropivacaine [INN] Ropivacainum [INN-Latin] S-Ropivacaine
  • ATC Code: N01BB09
  • Chemical Formula: C19H25NOS
  • Molecular Weight: 274.4011
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00296 (APRD00492)
  • SMILES: CCCN1CCCC[C,H]1C(=O)NC1=C(C)C=CC=C1C
  • InChl: ZKMNUMMKYBVTFN-HNNXBMFYSA-N
  • PubChem: 175805
  • IUPAC: (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide

Additional Details

Indication:
Used in obstetric anesthesia and regional anesthesia for surgery.
Pharmacodynamics:
Ropivacaine, a local anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
Mode of Action:
Local anesthetics such as Ropivacaine block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Specifically, they block the sodium-channel and decrease chances of depolarization and consequent action potentials. In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers.
Metabolism:
Hepatic
Toxicity:
Systemic exposure to excessive quantities of ropivacaine mainly result in central nervous system (CNS) and cardiovascular effects Ð CNS effects usually occur at lower blood plasma concentrations and additional cardiovascular effects present at higher concentrations, though cardiovascular collapse may also occur with low concentrations. CNS effects may include CNS excitation (nervousness, tingling around the mouth, tinnitus, tremor, dizziness, blurred vision, seizures) followed by depression (drowsiness, loss of consciousness, respiratory depression and apnea). Cardiovascular effects include hypotension, bradycardia, arrhythmias, and/or cardiac arrest Ð some of which may be due to hypoxemia secondary to respiratory depression.
General Reference:
Weinberg G, Ripper R, Feinstein DL, Hoffman W: Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med. 2003 May-Jun;28(3):198-202. Pubmed Picard J, Meek T: Lipid emulsion to treat overdose of local anaesthetic: the gift of the glob. Anaesthesia. 2006 Feb;61(2):107-9. Pubmed Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB: Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. Anesthesiology. 2006 Jul;105(1):217-8. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos